{
    "nct_id": "NCT05369403",
    "official_title": "An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab",
    "inclusion_criteria": "* All participants must have prior treatment with dupilumab meeting one of the following conditions:\n\n  * Participants who stopped dupilumab treatment due to non-response, partial response, loss of efficacy must have been previously treated with dupilumab (at labeled dose level) for at least 4 months.\n  * Participants who stopped dupilumab treatment due to intolerance or adverse events (AEs) to the drug may enter the study with no required prior length of dupilumab treatment.\n  * Participants who stopped dupilumab treatment due to cost or loss of access to dupilumab (for example, insurance coverage) may enter the study with no required prior length of dupilumab treatment.\n* Participants who have chronic AD that has been present for ≥1 year before screening.\n* Have EASI ≥16 at baseline\n* Have IGA score ≥3 (Scale of 0 to 4) at baseline\n* Have ≥10% body surface area (BSA) of AD involvement at baseline\n* Have a history of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable.\n* Adolescents body weight must be ≥40 kg at baseline.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\n* Have a current infection or chronic infection with hepatitis B virus (HBV) at screening (that is, positive for hepatitis B surface antigen and/or polymerase chain reaction positive for HBV DNA\n* Have a current infection with hepatitis C virus (HCV) at screening (that is, positive for HCV RNA\n* Have an uncontrolled chronic disease that might require multiple intermittent uses of oral corticosteroids at screening, as defined by the investigator.\n* Have uncontrolled asthma that\n\n  * might require bursts of oral or systemic corticosteroids, or\n  * required the following due to ≥1 exacerbations within 12 months before baseline\n\n    * systemic (oral and/or parenteral) corticosteroid treatment, or\n    * hospitalization for >24 hours.\n* Have known liver cirrhosis and/or chronic hepatitis of any etiology.\n* Had Dupilumab treatment within 4 weeks prior to baseline\n* Had prior treatment with tralokinumab.\n* Treatment with topical agents: corticosteroids, calcineurin inhibitors, Janus Kinase (JAK) inhibitors, or phosphodiesterase-4 inhibitors, such as crisaborole within 2 weeks prior to baseline\n* Treatment with any of the following agents within 4 weeks prior to the baseline\n\n  * systemic immunosuppressive or immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate mofetil, IFN-gamma, azathioprine, methotrexate, and other immunosuppressants)\n  * small molecules (e.g. JAK inhibitors)\n  * phototherapy and photochemotherapy for AD",
    "miscellaneous_criteria": ""
}